Pliant Therapeutics Net Worth
Pliant Therapeutics Net Worth Breakdown | PLRX |
Pliant Therapeutics Net Worth Analysis
Pliant Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Pliant Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Pliant Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Pliant Therapeutics' net worth analysis. One common approach is to calculate Pliant Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Pliant Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Pliant Therapeutics' net worth. This approach calculates the present value of Pliant Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Pliant Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Pliant Therapeutics' net worth. This involves comparing Pliant Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Pliant Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Pliant Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pliant Therapeutics' net worth research are outlined below:
| Pliant Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 1.58 M. Net Loss for the year was (161.34 M) with profit before overhead, payroll, taxes, and interest of 9.69 M. | |
| Pliant Therapeutics currently holds about 163.6 M in cash with (116.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.36. | |
| Pliant Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Pliant Therapeutics to Participate in Upcoming Investor Events - Yahoo Finance |
Pliant Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pliant Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pliant Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Pliant Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pliant Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pliant Therapeutics backward and forwards among themselves. Pliant Therapeutics' institutional investor refers to the entity that pools money to purchase Pliant Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Polar Capital Holdings Plc | 2024-06-30 | 2 M | Deutsche Bank Ag | 2024-06-30 | 1.5 M | State Street Corp | 2024-06-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Geode Capital Management, Llc | 2024-09-30 | 1.3 M | Ra Capital Management, Llc | 2024-09-30 | 1.3 M | Pictet Asset Manangement Sa | 2024-06-30 | 1.2 M | Franklin Resources Inc | 2024-09-30 | 1 M | Candriam Luxembourg S.c.a. | 2024-06-30 | 833.2 K | Deep Track Capital, Lp | 2024-09-30 | 6 M | Blackrock Inc | 2024-06-30 | 5 M |
Follow Pliant Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 789.88 M.Market Cap |
|
Project Pliant Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.34) | (0.32) |
When accessing Pliant Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Pliant Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pliant Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Pliant Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pliant Therapeutics. Check Pliant Therapeutics' Beneish M Score to see the likelihood of Pliant Therapeutics' management manipulating its earnings.
Evaluate Pliant Therapeutics' management efficiency
Pliant Therapeutics has return on total asset (ROA) of (0.2815) % which means that it has lost $0.2815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4752) %, meaning that it created substantial loss on money invested by shareholders. Pliant Therapeutics' management efficiency ratios could be used to measure how well Pliant Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. At this time, Pliant Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 378.4 M in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 957.1 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 8.07 | 8.47 | |
| Tangible Book Value Per Share | 8.07 | 8.47 | |
| Enterprise Value Over EBITDA | (6.39) | (6.71) | |
| Price Book Value Ratio | 2.25 | 2.36 | |
| Enterprise Value Multiple | (6.39) | (6.71) | |
| Price Fair Value | 2.25 | 2.36 | |
| Enterprise Value | 1 B | 1.1 B |
The strategic initiatives led by Pliant Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 1.4 K | Quarterly Revenue Growth (1.00) | Return On Equity (0.48) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pliant Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pliant Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pliant Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pliant Therapeutics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 4th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 12th of July 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Pliant Therapeutics Earnings per Share Projection vs Actual
Pliant Therapeutics Corporate Management
| Hal MD | Scientific Board | Profile | |
| Mike Ouimette | Gen Sec | Profile | |
| Rik Derynck | Scientific Board | Profile | |
| Dean MD | Scientific Board | Profile | |
| Johannes Hull | Chief Officer | Profile | |
| MBA MD | CEO Pres | Profile | |
| Christopher Keenan | Vice Communications | Profile |
Additional Tools for Pliant Stock Analysis
When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.